PFIZER INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, 20549FORM 10-K(Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from toCommission file number 1-3619PFIZER INC.(Exact name of registrant as specified in its charter)Delaware13-5315170(State or other jurisdiction of incorporation or organization)( Employer Identification Number)235 East 42nd Street, New York, New York 10017(Address of principal executive offices) (zip code)(212) 733-2323(Registrant s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $.
ACIP Advisory Committee on Immunization Practices Akcea Akcea Therapeutics, Inc. ALK anaplastic lymphoma kinase Alliance revenues Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us Allogene Allogene Therapeutics, Inc. AML Acute Myeloid Leukemia Anacor Anacor Pharmaceuticals, Inc.
Download PFIZER INC.
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: